中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2014年
25期
1929-1932
,共4页
洪立立%郭志%于海鹏%李保国%司同国%刘长富
洪立立%郭誌%于海鵬%李保國%司同國%劉長富
홍립립%곽지%우해붕%리보국%사동국%류장부
高强度聚焦超声消融%结直肠肿瘤%药物疗法,联合
高彊度聚焦超聲消融%結直腸腫瘤%藥物療法,聯閤
고강도취초초성소융%결직장종류%약물요법,연합
High-intensity focused ultrasound ablation%Colorectal neoplasms%Drug therapy,combination
目的:评价低功率高强度聚焦超声( HIFU)联合化疗方案治疗晚期结肠癌伴盆腔转移患者的临床有效性及安全性。方法收集天津医科大学肿瘤医院2007年5月至2012年5月住院结直肠癌患者共46例,均伴盆腔转移病灶,按治疗方式分为HIFU联合替吉奥+奥沙利铂( SOX)化疗方案组( HIFU+SOX)20例,SOX化疗方案组26例,比较两组患者的有效性及安全性。结果两组无进展生存时间(PFS)分别为11.2个月(95%CI 9.8~12.7)和7.1个月(95%CI 5.8~8.4),差异有统计学意义( P=0.003),两组总生存时间( OS )分别为21.9个月(95%CI18.0~25.9)和16.9个月(95%CI 14.1~19.6),差异无统计学意义(P=0.072)。 HIFU+SOX组患者主要的3/4级不良反应为粒细胞减少(15%)、贫血(10%)、血小板减低(10%)、胃肠道反应(15%)、手足综合征(10%)等,与SOX组相比差异无统计学意义( P>0.05)。结论 HIFU+SOX方案可延长晚期结肠癌伴盆腔转移患者的无进展生存期,患者易于接受。
目的:評價低功率高彊度聚焦超聲( HIFU)聯閤化療方案治療晚期結腸癌伴盆腔轉移患者的臨床有效性及安全性。方法收集天津醫科大學腫瘤醫院2007年5月至2012年5月住院結直腸癌患者共46例,均伴盆腔轉移病竈,按治療方式分為HIFU聯閤替吉奧+奧沙利鉑( SOX)化療方案組( HIFU+SOX)20例,SOX化療方案組26例,比較兩組患者的有效性及安全性。結果兩組無進展生存時間(PFS)分彆為11.2箇月(95%CI 9.8~12.7)和7.1箇月(95%CI 5.8~8.4),差異有統計學意義( P=0.003),兩組總生存時間( OS )分彆為21.9箇月(95%CI18.0~25.9)和16.9箇月(95%CI 14.1~19.6),差異無統計學意義(P=0.072)。 HIFU+SOX組患者主要的3/4級不良反應為粒細胞減少(15%)、貧血(10%)、血小闆減低(10%)、胃腸道反應(15%)、手足綜閤徵(10%)等,與SOX組相比差異無統計學意義( P>0.05)。結論 HIFU+SOX方案可延長晚期結腸癌伴盆腔轉移患者的無進展生存期,患者易于接受。
목적:평개저공솔고강도취초초성( HIFU)연합화료방안치료만기결장암반분강전이환자적림상유효성급안전성。방법수집천진의과대학종류의원2007년5월지2012년5월주원결직장암환자공46례,균반분강전이병조,안치료방식분위HIFU연합체길오+오사리박( SOX)화료방안조( HIFU+SOX)20례,SOX화료방안조26례,비교량조환자적유효성급안전성。결과량조무진전생존시간(PFS)분별위11.2개월(95%CI 9.8~12.7)화7.1개월(95%CI 5.8~8.4),차이유통계학의의( P=0.003),량조총생존시간( OS )분별위21.9개월(95%CI18.0~25.9)화16.9개월(95%CI 14.1~19.6),차이무통계학의의(P=0.072)。 HIFU+SOX조환자주요적3/4급불량반응위립세포감소(15%)、빈혈(10%)、혈소판감저(10%)、위장도반응(15%)、수족종합정(10%)등,여SOX조상비차이무통계학의의( P>0.05)。결론 HIFU+SOX방안가연장만기결장암반분강전이환자적무진전생존기,환자역우접수。
Objective To evaluate the efficacy and safety of the regimen of low-dose high intensity focused ultra-sound ( HIFU) plus S-1 and oxaliplatin ( SOX) in the treatment of metastatic colorectal cancer patients with pelvic masses.Methods A total of 46 patients with metastatic colorectal cancer were recruited and divided into 2 groups:Twenty patients received concurrent HIFU plus S-1 and oxaliplatin ( SOX) while another 26 patients SOX alone.The baseline characteristics , progressive-free survival , overall survival time and adverse events were retrospectively analyzed.Results The median PFS was 11.2 months ( 95% CI 9.8-12.7) in the HIFU+SOX group and 7.1 months (95%CI 5.8-8.4) in the SOX group ( P=0.003).And the overall survival time in two groups were 21.9 months ( 95% CI 18.0 -25.9 ) and 16.9 months (95%CI 14.1-19.6 ) ( P =0.072 ) respectively.Major toxic effects included grade 3/4 neutropenia (15%), anemia (10%), thrombocytopenia (10%), diarrhea (15%) and hand-foot syndrome (10%) in the HIFU +SOX group. And it showed no statistically significant differences with the SOX group.Conclusion The combined regimen of HIFU and SOX is effective and well-tolerated in patients of late-stage colorectal cancer with pelvic masses.